clinical trial · NCT06740526
Trial of the Impact of Sibeprenlimab on Immunoglobulin A Nephropathy Kidney Tissue
Otsuka Pharmaceutical Development & Commercialization, Inc.·phase2·recruiting·n = 25
IgA NephropathySibeprenlimab
brief summary
This is a phase 2b open-label trial to characterize histopathological biomarkers of disease in immunoglobulin A nephropathy (IgAN) and demonstrate potential changes in response to sibeprenlimab.
started
Nov 19, 2024
primary completion
Apr 17, 2029
completion
Apr 17, 2029
last updated
Apr 6, 2025
official title
A Phase 2b, Multicenter, Open-label, Single-arm Trial to Evaluate the Impact of Sibeprenlimab on Kidney Histopathology Through Repeat Kidney Biopsies in Adolescents and Adults With Immunoglobulin A Nephropathy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol